Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 11/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30147981 | 0.84 | LPL (0.39) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL21929765 | 0.80 | NAMPT (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL3308241 | 0.78 | PIK3CG (0.39) | LPLLIPGPIK3CDPIK3CGPIK3CA | |
| SCHEMBL20480347 | 0.76 | PIK3CG (0.47) | LPLLIPGPIK3CGCA1CA2 | |
| SCHEMBL935986 | 0.75 | PIK3CG (0.53) | PIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL1820427 | 0.73 | LPL (0.40) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL14658714 | 0.70 | LPL (0.40) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL17492388 | 0.69 | LPL (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL22480047 | 0.69 | PIK3CG (0.35) | LPLLIPGPIK3CDPIK3CGPIK3CA | |
| SCHEMBL22479933 | 0.69 | PIK3CG (0.36) | LPLLIPGPIK3CDPIK3CGPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3347361-B1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2020-08-05 | — | — | EP | disclosed |
| EP-3347361-B1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2020-08-05 | — | — | EP | disclosed |
| US-10435414-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-10435414-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180327420-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-11-15 | — | — | US | disclosed |
| US-10065970-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| EP-3347361-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | H. Hoffnabb-La Roche Ag (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| WO-2017042182-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017042182-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-16 | — | — | WO | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435414-B2 | Tricyclic PI3K inhibitor compounds and methods of use | PIK3CA, PIK3CD, PIK3CB | LPL 1826/4885LIPG 1239/4885PIK3CD 2/4885 |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | LPL 1826/4885LIPG 1239/4885PIK3CD 2/4885 |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | LPL 1826/4885LIPG 1239/4885PIK3CD 2/4885 |
| US-20180327420-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | LPL 1826/4885LIPG 1239/4885PIK3CD 2/4885 |
| US-10065970-B2 | Tricyclic PI3K inhibitor compounds and methods of use | PIK3CA, PIK3CD, PIK3CB | LPL 1826/4885LIPG 1239/4885PIK3CD 2/4885 |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | LPL 3774/4885LIPG 3175/4885PIK3CD 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.